Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Artiva Biotherapeutics, Inc.

ARTV Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2023–FY2025

Artiva Biotherapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

Add to portfolio Download report

Last close Β· Oct 23, 2026

$6.15

0.8%

What Artiva Biotherapeutics, Inc. does

ARTV Β· Biological Products, (No Diagnostic Substances)

From its latest annual report

No business description yet.

Filing details

Legal name
Artiva Biotherapeutics, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 10, 2026
Accession Β· CIK
0001193125-26-100135 Β· 0001817241

Earnings calendar Β· Artiva Biotherapeutics, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Artiva Biotherapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 11, 2026

Wednesday Β· in 16 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.54
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 6, 2026 Q2 '26 After the market closes 8-K β†—
May 8, 2026 Q1 '26 Before the market opens 8-K β†—
Mar 10, 2026 Q4 '25 After the market closes 8-K β†—
Nov 12, 2025 Q3 '25 Before the market opens 8-K β†—
Aug 6, 2025 Q2 '25 After the market closes 8-K β†—
May 8, 2025 Q1 '25 Before the market opens 8-K β†—
Mar 24, 2025 Q4 '24 After the market closes 8-K β†—
Nov 12, 2024 Q3 '24 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Artiva Biotherapeutics, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

4 to watch

Artiva Biotherapeutics, Inc. in 30 seconds

Good So-so Weak

Weak

Are sales growing?

βˆ’100.0%

No. Sales fell 100.0% last year.

Weak

Does it make a profit?

βˆ’$83.9M

No. It lost money last year.

Weak

How healthy are the accounts?

1 / 7

Weak. It passes 1 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$242M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$3.31 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Artiva Biotherapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Artiva Biotherapeutics, Inc. lost $83.9M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$79.3M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Artiva Biotherapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Artiva Biotherapeutics, Inc. lost $83.9M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$79.3M in fiscal 2025, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders bought $109M and sold $2.5M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$109M

7 insiders

Sold, 12 months

$2.5M

5 insiders

Of sales under plans

23%

$0.6M

DateInsiderTradeSharesPriceValueFiling
Oct 6, 2026 Fred AslanChief Executive Officer, Director Sold plan 23,463 $7.20 $0.2M Form 4
Oct 5, 2026 Subhashis BanerjeeChief Medical Officer Sold 1,099 $6.84 $0.0M Form 4
Oct 5, 2026 Christopher HoranChief Tech Operations Officer Sold 10,340 $6.84 $0.1M Form 4
Oct 5, 2026 Jennifer BushCOO, CLO, Compliance Officer Sold 8,370 $6.84 $0.1M Form 4
Oct 5, 2026 Fred AslanChief Executive Officer, Director Sold 61,696 $6.84 $0.4M Form 4
Sep 8, 2026 Fred AslanChief Executive Officer, Director Sold plan 23,429 $10.92 $0.3M Form 4
Sep 3, 2026 Christopher HoranChief Tech Operations Officer Sold 10,366 $11.16 $0.1M Form 4
Sep 3, 2026 Subhashis BanerjeeChief Medical Officer Sold 1,100 $11.16 $0.0M Form 4
Sep 3, 2026 Jennifer BushCOO, CLO, Compliance Officer Sold 8,391 $11.16 $0.1M Form 4
Sep 3, 2026 Fred AslanChief Executive Officer, Director Sold 61,888 $11.16 $0.7M Form 4
Aug 27, 2026 Subhashis BanerjeeChief Medical Officer Sold plan 8,222 $12.01 $0.1M Form 4
Aug 18, 2026 Subhashis BanerjeeChief Medical Officer Sold plan 429 $12.00 $0.0M Form 4
Jul 31, 2026 RA Capital Healthcare Fund LPDirector, 10% owner Bought 24,944 $9.93 $0.2M Form 4
Jul 29, 2026 RA Capital Healthcare Fund LPDirector, 10% owner Bought 20,824 $9.99 $0.2M Form 4
Jul 24, 2026 RA Capital Nexus Fund III, L.P.Director Bought 41,319 $9.99 $0.4M Form 4
Jul 23, 2026 Peter KolchinskyDirector, 10% owner Bought 59,880 $9.96 $0.6M Form 4
Jul 22, 2026 Peter KolchinskyDirector, 10% owner Bought 84,124 $9.93 $0.8M Form 4
Jul 21, 2026 Peter KolchinskyDirector, 10% owner Bought 120,582 $9.55 $1.2M Form 4
Jul 17, 2026 RA Capital Healthcare Fund LPDirector, 10% owner Bought 7,882 $8.95 $0.1M Form 4
Jul 16, 2026 RA Capital Healthcare Fund LPDirector, 10% owner Bought 152,472 $8.93 $1.4M Form 4
Jul 13, 2026 Rajeev M. ShahDirector, 10% owner Bought 6,552 $8.94 $0.1M Form 4
Jul 10, 2026 Rajeev M. ShahDirector, 10% owner Bought 15,102 $8.97 $0.1M Form 4
Jun 26, 2026 Ra Capital Management, L.P.Director, 10% owner Bought 1,876 $8.98 $0.0M Form 4
Jun 25, 2026 Ra Capital Management, L.P.Director, 10% owner Bought 31,000 $8.88 $0.3M Form 4
Jun 16, 2026 Peter KolchinskyDirector, 10% owner Bought 124,893 $8.89 $1.1M Form 4
Jun 15, 2026 Peter KolchinskyDirector, 10% owner Bought 15,414 $8.99 $0.1M Form 4
Jun 12, 2026 Peter KolchinskyDirector, 10% owner Bought 391,019 $8.57 $3.4M Form 4
Jun 11, 2026 RA Capital Nexus Fund, L.P.Director Bought 548,580 $7.91 $4.3M Form 4
Jun 10, 2026 RA Capital Nexus Fund, L.P.Director Bought 103 $7.00 $0.0M Form 4
Jun 9, 2026 RA Capital Nexus Fund, L.P.Director Bought 479,039 $6.91 $3.3M Form 4
May 19, 2026 Christopher HoranChief Tech Operations Officer Sold 7,002 $9.01 $0.1M Form 4
May 19, 2026 Subhashis BanerjeeChief Medical Officer Sold 7,037 $9.01 $0.1M Form 4
May 19, 2026 Jennifer BushCOO, CLO, Compliance Officer Sold 8,790 $9.01 $0.1M Form 4
May 19, 2026 Heather RaymonSVP, Research and Development Sold 3,095 $9.01 $0.0M Form 4
May 19, 2026 Fred AslanChief Executive Officer, Director Sold 27,116 $9.01 $0.2M Form 4
May 11, 2026 RA Capital Nexus Fund III, L.P.Director Bought 6,510,416 $11.52 $75.0M Form 4
May 11, 2026 GC Corp.10% owner Bought 1,432,291 $11.52 $16.5M Form 4
Dec 15, 2025 Fred AslanPresident and CEO, Director Sold plan 3,187 $6.00 $0.0M Form 4
Nov 17, 2025 Fred AslanPresident and CEO, Director Sold plan 6,375 $3.38 $0.0M Form 4
Oct 17, 2025 Fred AslanPresident and CEO, Director Sold plan 25,500 $6.00 $0.2M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Artiva Biotherapeutics, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY23FY24FY25
Cash and short-term investments $77.0M$185M$108M
Current ratio 6.5x15.4x8.6x
Quick ratio 6.5x15.4x8.6x
Total assets $105M$210M$131M
Total liabilities $50.7M$22.9M$21.0M
Shareholders' equity βˆ’$162M$187M$110M
Net debt (βˆ’ = net cash) β€”β€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Artiva Biotherapeutics, Inc. passes 1 of 7 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY23FY24FY25
Net income is positive βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ•
Return on assets rose β€” βœ• βœ•
Cash from operations exceeds net income βœ• βœ“ βœ“
Debt fell relative to assets β€” β€” β€”
Current ratio rose β€” βœ“ βœ•
Share count didn't rise β€” βœ• βœ•
Gross margin rose β€” β€” β€”
Revenue rose relative to assets β€” βœ• βœ•
F-score β€” / 32 / 71 / 7
Accruals ratio 17.8%βˆ’6.6%βˆ’4.2%
Altman Z'' βˆ’6.728.07βˆ’2.34

All figures

Every number, year by year.

3 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY23FY24FY25
Income statement
Revenue $33.5M $0.3M $0.0M
Research and development $50.3M $50.3M $69.5M
Operating income βˆ’$30.7M βˆ’$67.3M βˆ’$89.8M
Pretax income βˆ’$28.6M βˆ’$65.4M $83.9M
Income tax $0.1M $0.0M $0.0M
Net income βˆ’$28.7M βˆ’$65.4M βˆ’$83.9M
Diluted EPS βˆ’$35.78 βˆ’$5.81 βˆ’$3.43
Diluted shares 0.00B 0.01B 0.02B
Cash flow
Cash from operations βˆ’$47.4M βˆ’$55.0M βˆ’$76.8M
Capital expenditure $3.3M $0.6M $2.6M
Free cash flow βˆ’$50.7M βˆ’$55.7M βˆ’$79.3M
Depreciation and amortization $2.3M $2.4M $2.6M
Stock-based compensation $7.1M $7.0M $6.8M
Balance sheet
Cash and short-term investments $77.0M $185M $108M
Current assets $79.8M $189M $113M
Current liabilities $12.2M $12.3M $13.1M
Property and equipment, net $8.1M $6.4M $6.6M
Total assets $105M $210M $131M
Total liabilities $50.7M $22.9M $21.0M
Shareholders' equity βˆ’$162M $187M $110M
Margins
Operating margin βˆ’91.6% βˆ’26,805.6% β€”
EBITDA margin βˆ’84.8% βˆ’25,837.1% β€”
Net margin βˆ’85.8% βˆ’26,045.0% β€”
FCF margin βˆ’151.3% βˆ’22,180.9% β€”
Returns
Return on capital employed βˆ’33.0% βˆ’34.1% βˆ’76.2%
Return on equity β€” βˆ’530.9% βˆ’56.5%
Return on assets βˆ’27.3% βˆ’41.5% βˆ’49.3%
Return on tangible equity β€” βˆ’35.0% βˆ’76.3%
Growth
Revenue growth β€” βˆ’99.3% βˆ’100.0%
Share count change β€” 1,302.6% 117.1%
Financial health
Current ratio 6.5x 15.4x 8.6x
Quick ratio 6.5x 15.4x 8.6x
Capital allocation
Capex / revenue 9.7% 255.8% β€”
Stock comp / revenue 21.1% 2,780.9% β€”
Quality scores
Piotroski F-score β€” 2.0 1.0
Altman Z'' βˆ’6.7 8.1 βˆ’2.3
Accruals ratio 17.8% βˆ’6.6% βˆ’4.2%

Source: SEC EDGAR XBRL filings (CIK 0001817241). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open